image header

Investor Overview

Investor Overview

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.

ALX Oncology


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Nov 8, 2022

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Read more

Nov 3, 2022

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting Read more

Nov 2, 2022

ALX Oncology Announces Upcoming Investor Conference Participation Read more

Upcoming Events

Nov 29, 2022 at 9:00 AM EST

Piper Sandler 34th Annual Healthcare Conference